Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.
Anticancer Res
; 35(5): 3097-102, 2015 May.
Article
in En
| MEDLINE
| ID: mdl-25964601
ABSTRACT
AIM:
The aim of the study was to evaluate the activity and safety of reduced-dose abiraterone acetate (AA) in ≥ 85 year-old patients with advanced castrate-resistant prostate cancer (CRPC). PATIENTS ANDMETHODS:
Patients received 750 mg oral AA as three 250-mg tablets once daily, with concomitant oral prednisone, 5 mg daily.RESULTS:
Twenty-six patients were enrolled; median age was 88 years (range=85-93). Prostate-specific antigen (PSA) response was observed in 18 (69.2%) subjects, median time to PSA progression was 6.4 months (95% confidence interval (CI)=2.8-8.8) and median overall survival was 14.3 months (95% CI=7.2-18.3). The treatment was well-tolerated and adverse events, related to mineralocorticoid excess, were of grade 1-2 in all patients.CONCLUSION:
Reduced dose of AA combined with a very low dose of prednisone is effective and well-tolerated in very elderly patients with advanced CRPC.Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prednisone
/
Antineoplastic Combined Chemotherapy Protocols
/
Prostatic Neoplasms, Castration-Resistant
/
Androstenes
Limits:
Aged80
/
Humans
/
Male
Language:
En
Journal:
Anticancer Res
Year:
2015
Document type:
Article
Affiliation country: